TEL AVIV & WENDELSHEIM, Germany – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with...
finance News
BETHESDA, Md. – The Cystic Fibrosis Foundation affirmed its support for the PASTEUR Act, a bipartisan proposal that, if passed, will support the development of new antibiotics and promote appropriate use of existing ones. The organization issued the following statement: “New solutions are needed now to bring novel antibiotics into...
PRINCETON, N.J. – The McQuade Center for Strategic Research and Development, LLC (MSRD), a member of the global Otsuka family of pharmaceutical companies, announces today that it has entered an agreement with Sentinel Oncology (Sentinel), a drug discovery company. The McQuade Center for Strategic Research and Development at Otsuka in...
United States Sens. Tim Kaine (D-VA), Mark R. Warner (D-VA), Jerry Moran (R-KS) and Bill Cassidy (R-LA) introduced Thursday the Gabriella Miller Kids First Research Act 2.0, which would provide additional funding for childhood cancer research. The bill is named in honor of Gabriella Miller, a Leesburg resident who died...
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. – United Therapeutics (Nasdaq: UTHR), a public benefit corporation with a purpose to provide a brighter future for patients, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2022. This award is presented by Newsweek...
Encinitas, Calif. — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, announced financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent pipeline...
SAN FRANCISCO – Today, VeriSIM Life (VeriSIM) announces the launch of its pharmaceutical subsidiary, PulmoSIM Therapeutics (PulmoSIM) with the mission to address the unmet needs in the treatment of rare respiratory diseases, with an immediate emphasis on pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). PulmoSIM is developing breakthrough...
BOSTON & CAMBRIDGE, Mass. – Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and Obsidian Therapeutics announced today that the two companies have entered into a strategic research collaboration and licensing agreement focused on the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The collaboration leverages Obsidian’s cytoDRiVE®...
LEIDEN, Netherlands — Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced a $60 million (€54 million) Series B financing. The financing was led by new investor Ackermans & van Haaren (AvH) with existing co-leads Droia Ventures, EQT Life Sciences and Kurma Partners...
SAN DIEGO — Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per...